Teleflex Incorporated

Teleflex Incorporated

TFXNYSE / NASDAQHealthcareMid cap

$161.58-$1.82 (-1.1%)

Last close · Data as of Nov 20, 2026

Market cap
$5.8B
P/E
-6.5x
EV / EBITDA
27.1x
Revenue
$2.0B
Net margin
-45.4%
ROCE
4.1%

+54.4% over the last year

Teleflex Incorporated price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+23.2%
3M
+19.7%
6M
+19.5%
1Y
+54.4%
5Y
-49.3%

52-week range

Day change -$1.82 (-1.1%) from $163 to $162 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in TFX, bought on each weekday since 2021.

News & filings

What Teleflex Incorporated filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 906 million US dollars in fiscal 2025.

Strengths (1)

  • The price is 25.3% above its 200-day average, and the 50-day average is above the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally.

Read moreShow less

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters. In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands. It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Sector
Healthcare
Shares outstanding
44.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$5.8B
P/E
-6.5x
P/B
1.9x
EV / EBITDA
27.1x
EV / Sales
4.1x
P/S
2.9x
52-week high
$165.85
52-week low
$100.34

Profitability

Operating margin
12.8%
Net margin
-45.4%
EBITDA margin
15.2%
ROE
-29.0%
ROCE
4.1%
ROA
-13.0%
Asset turnover
0.29

Growth

Revenue
$2.0B
Revenue growth, 1Y
17.2%
Revenue CAGR, 3Y
-10.6%
Net profit growth, 1Y
-1399.8%
Free cash flow
$245.4M

Solvency

Current ratio
2.54
Debt / Equity
0.87
Debt / Assets
0.39
CFO / Net profit
-0.38
Cash / Market cap
6.5%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$2.0B
Cost of revenue$872.0M
Gross profit$1.1B
Operating expenses$865.0M
Research and development$144.8M
Selling, general and administrative$720.2M
Operating income$255.8M
Interest and other-$231.3M
Pretax income$24.6M
Tax and other$930.2M
Net income-$905.6M

Revenue and net profit

Revenue grew 17.2% in FY2025; net profit is the dashed line.

Teleflex Incorporated revenue and net profit by fiscal year
Teleflex Incorporated revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$2.8B$363.1M
FY2023$1.7B$356.3M
FY2024$1.7B$69.7M
FY2025$2.0B-$905.6M

Cash flows

FY2025: $340.7M from operations, $245.4M free after investment (dashed).

Teleflex Incorporated operating and free cash flow by fiscal year
Teleflex Incorporated operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$342.1M$263.0M
FY2023$510.6M$464.2M
FY2024$635.7M$545.3M
FY2025$340.7M$245.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$2.0B+17.2%1Y
EBITDA
$302.5M+11.5%1Y
Net profit
-$905.6M-1,399.8%1Y
Cash from operations
$340.7M-46.4%1Y
Free cash flow
$245.4M-55.0%1Y
Revenue CAGR, 3Y
-10.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$2.0B$302.5M-$905.6M$245.4M-29.0%+17.2%-1399.8%

Monthly returns

Month-by-month returns of TFX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$6.9B
Liabilities$3.8B
Equity$3.1B
Paid-in capital$815.8M
Retained earnings$3.1B
Treasury stock$649.5M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; TFX highlighted.

P/E against peers

TFX has no positive P/E; the peer median is 17.5x.

Not shown (no positive earnings and no EV / Sales): Teleflex Incorporated, Glaukos Corporation, Protagonist Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Teleflex IncorporatedTFXthis company$5.8B-6.5x1.9x-29.0%27.1x
Alkermes plcALKS$7.2B29.9x4.0x13.3%20.9x
Glaukos CorporationGKOS$7.1B-38.1x10.9x-28.6%-49.0x
Protagonist Therapeutics, Inc.PTGX$6.6B-50.8x10.8x-21.2%-41.4x
TG Therapeutics, Inc.TGTX$6.2B13.9x9.6x69.0%47.5x
PTC Therapeutics, Inc.PTCT$5.9B8.6x—-332.5%7.5x
Apellis Pharmaceuticals, Inc.APLS$5.3B234.6x14.2x6.0%75.2x
Ligand Pharmaceuticals IncorporatedLGND$4.7B38.0x4.6x12.2%25.3x
Indivior Pharmaceuticals, Inc.INDV$4.4B21.1x-44.7x-212.1%15.1x
Peer median—17.5x9.6x-7.6%18.0x

Year-to-date ROI

TFX since 1 January, against earlier years.

Historical volatility

TFX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Teleflex Incorporated operating margin by fiscal year
Teleflex Incorporated operating margin by fiscal year
DateOperating margin
FY202218.4%
FY202317.7%
FY202414.9%
FY202512.8%
LineFY2025
Cost of revenueCost Of Revenue$872.0M
Gross profitGross Profit$1.1B
Operating expensesOperating Expense$865.0M
Research and developmentResearch And Development$144.8M
Selling, general and administrativeSelling General And Administration$720.2M
Total expensesTotal Expenses$1.7B
Pretax incomePretax Income$24.6M

Learn while you research

Academy chapters picked for Teleflex Incorporated and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →